|Bid||1.0300 x 1400|
|Ask||1.3700 x 3000|
|Day's Range||1.3100 - 1.3500|
|52 Week Range||0.9300 - 4.2300|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.02|
NantKwest, Inc. (NASDAQ:NK) shareholders should be happy to see the share price up 11% in the last month. But only the...
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors
NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and pharmaceutical sectors,” said Patrick Soon-Shiong, Chairman and CEO of NantKwest. Since 2008, Ms. Cohen has served as president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization.
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company today presented a clinical data update in patients who have received off-the-shelf aNK and/or haNK natural killer cell therapy in combination with immunotherapeutic agents in advanced solid tumors.
NantKwest Inc. (Nasdaq:NK) announced today that its strategic partner Viracta Therapeutics presented updated clinical data on its HDAC inhibitor, nanatinostat (VRx-3996) at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from May 31st – June 4th, 2019. In April 2017, NantKwest announced that it was the lead investor in Viracta’s Series B financing round. Concurrent with the financing, NantKwest secured an exclusive license with commercialization rights to nanatinostat for use in combination with natural killer (NK) cell therapies, including NantKwest’s NK cell platforms.
NantKwest Inc. (NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that the company’s t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma.
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019. The presentations and one-on-one discussions will feature a science/medicine review, along with a clinical update provided by Dr. Soon-Shiong and Company management.
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Inte
Brink Biologics, Inc., a NantKwest, Inc. (NK) affiliate who serves as exclusively-licensed distributor of NantKwest’s proprietary NK-92® natural killer cells, offers a variety of research grade aNK™ and haNK® cell lines for non-clinical laboratory use in discovery, translational and developmental research and lot release testing for commercial products ranging from monoclonal antibodies, bi-specific biologics, cytokines and other bioactive products.
NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has been issued a new patent that further expands the Company’s foundational natural killer cell-therapeutics platform intellectual property estate. This new patent builds upon NantKwest’s extensive existing patent estate and broadens the Company’s established intellectual property combining haNK natural killer cell therapy together with antibody therapy.
NantKwest (NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company’s Chairman & CEO, on March 21, 2019, exercised 17,589,250 warrants with an exercise price of $1.9984 and 1,851,000 options with an exercise price of $2.1983, representing an aggregate cash exercise price of $39.2.
NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong, will be giving a keynote address at the Innate Killer Summit in San Diego on Wednesday, March 20, 2019. Dr. Soon-Shiong’s keynote address will provide a vision of next generation NK cell therapies and feature a review of translational R&D activities, state-of-the-art manufacturing requirements, along with clinical progress. “Over a few short years, the cell therapy industry has made significant progress with remarkable patient responses to therapy being seen in a few select cancer indications.
NantKwest, Inc. (NK), a leading clinical-stage Natural Killer (NK) cell based therapeutics company, and ProMab Biotechnologies today announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with an option for up to five undisclosed targeting sequences for exclusive use in the development of chimeric antigen receptor (CAR) based NK cell therapies.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2015 Patrick Soon-Shiong was appointed CEO of NantKwest, Inc.Read More...
NantKwest’s phase II immunotherapy trial builds upon the company’s earlier phase II single-combination study using its proprietary, off-the-shelf aNKTM natural killer cell therapy and IL-15/Fc superagonist (N-803), which produced an objective responses in 3 of 7 patients.
NantCell, a cancer treatment company founded by biotech entrepreneur Dr. Patrick Soon-Shiong, has received an additional $30 million investment from drug maker Celgene Corp.
NantKwest (NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases today announced that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California. At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide a roadmap for the company’s clinical programs for 2019.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
Novel Trisprcific CD19.t-haNKTM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma
CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / The US healthcare market is seeing a higher levels of acquisition activity as providers race to capitalize on innovation and deliver a better consumer experience. Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest said, "High dose, uninformed, toxic chemotherapy damages the immune system and induces what is known as tolerogenic cell death.